Endologix, Inc.  

(Public, NASDAQ:ELGX)   Watch this stock  
Find more results for Daniel M. McDermott�
+0.17 (1.40%)
Real-time:   12:55PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.13 - 12.44
52 week 11.47 - 18.85
Open 12.13
Vol / Avg. 101,237.00/945,759.00
Mkt cap 786.87M
P/E     -
Div/yield     -
EPS -0.26
Shares 63.87M
Beta 1.11
Inst. own 97%
May 22, 2014
Endologix Inc. Annual Shareholder Meeting - 11:00AM EDT - Add to calendar
Apr 28, 2014
Q1 2014 Endologix Inc. Earnings Release (Estimated) Add to calendar
Mar 18, 2014
Endologix Inc. at Lazard MedTech, Diagnostics & Healthcare IT Snowbird Conference
Mar 10, 2014
Endologix Inc. at ROTH Conference
Feb 27, 2014
Q4 2013 Endologix Inc. Earnings Conference Call - Webcast
Feb 27, 2014
Q4 2013 Endologix Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -9.68% -12.15%
Operating margin -12.60% -14.27%
EBITD margin - -6.02%
Return on average assets -6.41% -7.63%
Return on average equity -13.84% -16.14%
Employees 482 -
CDP Score - -


IRVINE, CA 92618
United States - Map
+1-949-5957200 (Phone)
+1-949-4579561 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Endologix, Inc. (Endologix) is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company�s principal product is a stent graft and delivery system (ELG System), for the treatment of abdominal aortic aneurysms (AAA) through endovascular repair (EVAR). Its ELG System consists of a self-expanding cobalt chromium alloy stent covered by expanded polytetrafluoroethylene (ePTFE) graft material (ELG Device) and an accompanying delivery catheter. Once its ELG Device is fixed in its proper position within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. Its ELG System consists of the Company�s ELG Device and catheter delivery system. It also offers proximal aortic extensions and limb extensions, which attach to the main body of its ELG Device.

Officers and directors

John McDermott Chairman of the Board, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Robert D. Mitchell President
Age: 51
Bio & Compensation  - Reuters
Shelley B. Thunen Chief Financial Officer and Corporate Secretary
Age: 61
Bio & Compensation  - Reuters
Leo M. Greenstein Vice President - Finance, Corporate Controller
Age: 37
Bio & Compensation  - Reuters
Todd G. Abraham Vice President - Operations
Age: 49
Bio & Compensation  - Reuters
Joseph A. DeJohn Vice President - Sales
Age: 52
Bio & Compensation  - Reuters
Ruth Lyons Vice President - Global Marketing
Age: 57
Bio & Compensation  - Reuters
Dave Jennings Vice President - Human Resources
Bio & Compensation  - Reuters
Charles Love Vice President - Clinical Affairs
Age: 51
Bio & Compensation  - Reuters
Gary I. Sorsher Vice President - Quality
Age: 48
Bio & Compensation  - Reuters